BAYER ANNOUNCES DATA FROM STUDY COMPARING LEVITRA, VIAGRA
Bayer announced that a head-to-head study comparing the company's drug Levitra (vardenafil) with Viagra (sildenafil) in patients with erectile dysfunction and risk factors for cardiovascular disease shows that in those men who expressed a preference, 53 percent preferred vardenafil compared with 47 percent who preferred sildenafil. This study demonstrated Levitra's non-inferiority to sildenafil for overall preference and achieved nominal statistical superiority to sildenafil for several frequently used efficacy measures.
The CONFIRMED Study is a randomized, double-blind, pooled, crossover study. This study compared patient preference and satisfaction with the two treatments in men with erectile dysfunction and diabetes, hypertension and/or hyperlipidaemia in Europe, the U.S. and Mexico. Patients underwent two 4-week treatment periods and received either vardenafil 20 mg or sildenafil 100 mg.
A total of 1,057 men were recruited, of which 38.9 percent expressed an overall preference for Levitra over Viagra and 26.6 percent had no treatment preference. And vardenafil achieved nominal statistical superiority to sildenafil for several other frequently used efficacy measures.
Researchers minimized bias through equivalent drug doses, a randomized treatment sequence and a neutral consent form, and they assessed preference after each treatment period and did not eliminate previous non-responders or only include naive patients, according to Bayer.
Upcoming Events
-
21Oct